Torrent Pharma: consolidated PAT falls 9.6% YoY to ₹534 Cr despite 51% revenue surge
PAT -9.6% YoY · revenue +50.8% · margins compressing · beat vs street
₹4,979 Cr
+50.8% YoY
₹534 Cr
-9.6% YoY
10.75%
-7.3pp YoY
₹14.05
Torrent Pharmaceuticals' consolidated (primary) Q2 FY27 revenue was ₹4,979 Cr, up 50.8% YoY and 1.2% QoQ, while PAT fell 9.6% YoY to ₹534 Cr (down 5.7% QoQ from ₹566 Cr). The headline revenue jump is largely inorganic: J.B. Chemicals, amalgamated into Torrent effective 8 July 2026 (NCLT-approved scheme, appointed date 21 January 2026), contributed ₹1,086 Cr of the ₹4,979 Cr total; the like-for-like base business grew a steadier 18% YoY to ₹3,893 Cr. Standalone PAT was ₹498 Cr, down a steeper 16.6% YoY — consolidated earnings held up relatively better because they capture JB's subsidiaries for the full quarter, while acquisition debt sits mostly at the standalone/parent level.
Q2 FY-2027 vs prior quarters
Operating performance was actually strong: consolidated Op. EBITDA was ₹1,666 Cr, up 53.8% YoY, with margin expanding to 33.5% from 32.8%. The net margin compression (NPM 10.7% vs 17.9% YoY, 11.5% QoQ) sits entirely below the EBITDA line — finance costs jumped to ₹300 Cr from ₹48 Cr and depreciation & amortisation to ₹609 Cr from ₹204 Cr, both consequences of debt-funding the JB acquisition (consolidated debt-equity now 0.76x vs 0.31x) and amortising the ₹23,352 Cr of intangibles recognised on purchase accounting. Exceptional items were minor and roughly flat YoY, so adjusting for them barely moves the picture — adjusted PAT is still down about 9.9% YoY. The drag is structural (financing and amortisation), not a one-off.
The stock went into the print at ₹4,524.4, down 8.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY27: JB India Rx double-digit growth, international high single-digit to low double-digit constant currency. Base business EBITDA margin trajectory 0.5% annual improvement. Cost synergies >₹100 Cr (vs ₹90 Cr prior). Semaglutide guidance withdrawn pending recovery trajectory observation.
— This quarter: missed
Against FY27 guidance set on the Q1 call — JB India Rx double-digit growth and international high-single to low-double-digit constant-currency growth — the quarter missed on both: JB India Rx (ex trade generics/contrast media) grew just 7% YoY to ₹597 Cr (H1 at 10%, right on the guided line), and JB International revenue fell 7% YoY to ₹406 Cr. Base EBITDA margin improved ~70bps YoY, broadly in line with the guided ~50bps annual pace. No quarter-specific street PAT/revenue consensus could be confirmed via search; against the pre-result preview's EBITDA margin expectation of 24-26%, the actual 33.5% Op. EBITDA margin beat that marker comfortably. Base India revenue grew 20% YoY against 12% IPM growth (PharmaTrac), and Brazil grew 38% reported (20% constant currency) against 6% market growth — both ahead of market.
W1
JB India Rx growth trajectory toward the double-digit FY27 guidance — currently +7% YoY this quarter, +10% for H1
W2
Finance cost (₹300 Cr) and D&A (₹609 Cr) run-rate as integration settles, and progress toward the >₹100 Cr cost-synergy target (not yet quantified)
W3
Gx Semaglutide combined market share (32% in Q2 FY27 per PharmaTrac) — formal financial guidance on this product remains withdrawn
Standalone is audited; consolidated is unaudited (limited review) — matches filing. Exceptional items (₹10 Cr litigation settlement vs ₹13 Cr M&A-related costs YoY) are small and nearly offsetting; PAT drag is from finance cost and D&A, not exceptionals. NCI derecognised post-merger effective 8-Jul-2026.
Merger momentum & margin accretion on deck — first full quarter post-JB integration
Torrent Pharma's first full standalone quarter after the July JB Chemicals merger will test integration execution and margin expansion. The Street backs the deal, with consensus lifted to ₹5,387 and growth intact despite recent management churn.
The setup: merger accretion & integration test
Torrent Pharma's Q2 FY27 print will be the market's first real-time read on the JB Chemicals amalgamation — which closed Jul 8, 2026, with a retroactive appointment date of Jan 21. While Q1 captured a partial quarter of integration, Q2 is the first clean, full-quarter comparison of the merged entity. The Street's focus: does revenue scale materialize, can management sustain EBITDA margins into the mid-to-high 24% range, and what's the timing on synergy capture?
~₹35–38 Cr
Organic+merger boost; FY27 guidance ₹130.6 Cr implies ~₹32–33 Cr/qtr baseline; merger adds incremental JB contribution
~24–26%
On-plan accretion from merger scale; watch for one-time costs vs synergy capture
Domestic chronic + BGX + Brazil
JB brings chronic powerhouse brands; Brazil momentum cited by analysts as key unlock
Buy across 29 analysts
Average target raised to ₹5,387 (from ₹5,084); targets range ₹4.7K–₹6.2K
A strong print would show organic growth in Torrent's domestic chronic and specialty segments intact, JB's legacy revenue flowing through with no material churn, and EBITDA margins holding or expanding into the 24–26% zone. A weak print would flag customer losses post-acquisition, margin pressure from integration costs running longer than guided, or sluggish Brazil uptake.
On track? The guidance roadmap
Full-year FY27 consensus (29 analysts) pins revenue at ₹130.6 Cr and statutory EPS growth at 15% to ₹72.69. The merger is baked into these numbers as a synergy engine. Q2 will test whether the 3-month integration window (post-closure) has yielded the operational glue the deal model promised — cross-selling, duplicate-function elimination, CDMO capacity scaling. Management cited the deal as long-term earnings accretion; this quarter should show visible momentum on that claim, especially in the chronic and ophthalmo segments where JB adds breadth.
Since last quarter: filings and operational flags
1 · JB Chemicals merger closed (Jul 8, 2026)
Amalgamation completed with retroactive Jan 21 appointment date. Company issued 4.19 Cr equity shares to JB shareholders; shares listed on NSE/BSE Jul 17. This is the transformative event anchoring Q2 expectations.
2 · Management turnover
Amal Kelshikar (Executive Director, SMP) resigned effective Oct 16, 2026 — the day results announcement window closed. Three other SMPs (Hasmukh Patel, Sushil Jaiswal, Sunil Nadkarni) exited Jul 30, 2026, in conjunction with merger integration. Routine transitions, but signal integration is underway.
3 · Semalix product recall (Jul 9, 2026)
Voluntary recall of select Semalix injection disposable pens (2 mg, 4 mg) as precautionary measure, following OEM notification. Impact likely immaterial to Q2 financials given late-July timing and precautionary nature.
4 · Capex expansion: Torrent Urja power investment (Sep 28, 2026)
Investment in Torrent Urja 27 (captive hybrid power project) increased from ₹7.92 Cr to ₹11.88 Cr. Signals sustained capex discipline; immaterial to quarterly P&L but shows operational momentum.
What to watch on result day (Oct 23)
1. Merger revenue contribution & churn rate: How much of JB's legacy ₹~1,000 Cr+ annual revenue flows through Q2, and any customer attrition post-close? 2. EBITDA margin & one-time costs: Does margin expand to 24–26% zone, or are integration costs (restructuring, redundancy removal) weighing heavier than expected? 3. Guidance reiteration: Management should reaffirm FY27 consensus or update it; any downside surprise on synergy timing could spook the Street.
Torrent Pharma enters Q2 as a fundamentally different company — JB's bolt-on has scaled it into India's top-5 domestic player, but execution risk is front-and-center. The Street is constructive (Buy consensus, targets lifted to ₹5,387), pricing in margin accretion and Brazil upside. The quarter's job: prove the integration roadmap is on schedule and synergies are real. Strong margin, clean revenue flow, and management confidence on H2 outlook would validate the deal thesis and reignite momentum into a stock currently 13% off ATH and trading oversold (RSI 15.7).
Revenue surge masks PAT decline; integration ongoing, base business resilient
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
H1 India branded growth 10% aligns with prior double-digit target (H2 expected higher); international down 7% missed high single-digit to low double-digit guidance; base margin 0.5% improvement trajectory maintained but H2 specifics deferred.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 revenue growth of 50.8% is JB-merger-fueled, but net profit fell 9.6% YoY despite strong EBITDA growth—a signal that integration costs and competitive pressure are eroding profitability faster than top-line expansion. Base business is healthy (India +20%, Curatio +34%), and cost synergies are tracking ahead of plan, but near-term visibility is clouded by JB integration execution risk and international weakness (down 7% vs guidance).
₹4979 Cr
Revenue · +50.8% YoY₹534 Cr
Reported PAT · −9.6% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenues up 51% YoY
METDelivered 4979 Cr, +50.8% YoY — matches
Operating EBITDA margin 33.5%
METDelivered OPM 33.3% — within rounding
International business down 7%
MISSPrior guidance was high single-digit to low double-digit growth; -7% misses it
Base India business grew 20%
OVERSTATEDSpecific segment claim; overall India branded grew 7% post-integration
Cost synergies tracking higher, deliverable in 2 years vs 3
METPrior guidance '>₹100 Cr'; call signals acceleration but no new numeric target
H2 FY27 margins expected higher than Q2's 33.5%
PartialGuidance is directional; no specific FY27 margin target restated
Earnings quality
What changed since the last call
Cost synergy timeline accelerated
UpgradeFrom 3 years to 2 years; tracking higher than ₹100 Cr initial guidance. ~₹450 Cr estimated, roughly half in FY27. Faster realization is positive but deferred specificity on full quantum.
India branded growth H1 softer than H2 outlook
NeutralQ2 growth only 7% (vs 20% base business growth) due to JB integration; H2 expected 'perhaps higher than 10%'. Management expects recovery but execution risk remains.
EBITDA margin flat QoQ despite operational leverage
DowngradeQ2 EBITDA margin 33.3% (vs Q1 33.5% implied); prior guidance was 0.5% annual improvement. H2 expected to improve but quantification withheld. R&D spend increased to 4.2% (vs 3.5% Q1) as temporary investment.
Semaglutide recovery narrative refined
NeutralGuidance still withdrawn, but call provides recovery color: supply restored by Sep, market size ~₹800 Cr, company at 32% share. Stabilization expected but market size is early estimate.
The Q&A
Analysts pressed on JB profitability (EBITDA margin bridge, sequential improvement rate), cost synergy magnitude (upside vs ₹450 Cr estimate, timeline), and FY28 guidance (deferred; management unwilling to commit). Tone was persistent but not adversarial; management held line on cautious guidance and acknowledged execution uncertainty. Weak on specific numbers for JB recovery trajectory.
JB disruption & recovery — Neha Manpuria, Bank of America
PartialQ2 at 7%, Q1 at 13%. Expect gradual recovery; H2 total JB growth should recover to double-digit. Integration transient, actions being taken.
Cost synergies magnitude and timeline — Neha Manpuria, Bank of America
PartialTracking higher than initial ₹100 Cr guidance. Possibly ₹450 Cr by next year. Most could come through by next year; in 2 years instead of 3. No further upside detail given.
JB India business profitability — Kunal Dhamesha, Macquarie Capital
AnsweredYes, that's fair assumption. JB base business EBITDA margins improving, directional improvement expected for next 2-3 quarters. Exact sequential improvement not guided.
R&D spend sustainability — Nitin Agarwal, DAM Capital
AnsweredTemporary for 2-3 years; range 4% to 4.5% in coming year. Intended to recover filings in US and increase productivity in expanded divisions.
Brazil outlook and GLP-1 launch — Nitin Agarwal, DAM Capital
AnsweredBrazil optimistic for double-digit mid-teens growth; 53 products in ANVISA review. GLP-1 generic launch by local large player in last 3 months; Torrent expects launch in next 6-9 months.
US market dynamics and launches — Saion Mukherjee, Nomura
AnsweredFilings improved; 4 products filed YTD, expect 4-5 more before FY end. Market shares above expectations. Pricing pressure expected in H2; new launches should keep growth positive. Volume and new products offsetting price erosion.
Semaglutide market and share recovery — Tushar Manudhane, Motilal Oswal
AnsweredMarket size ~₹800 Cr for first year. Post-Sitagliptin pattern expected: high growth early years, stabilization by year 3-4. 2-2.5 Cr market possible after 3-4 years. On-track to recover.
India pharma market dynamics and IPM growth — Tushar Manudhane, Motilal Oswal
AnsweredH1 market growth 12% (above historical trend). Expect this to sustain or drop slightly to 10-11%. Minimum 10% growth expected; higher growth temporary due to semaglutide and field force expansion.
JB international disruption specifics — Kunal Dhamesha, Macquarie Capital
AnsweredAcross geographies due to integration (software, accounting, quality systems). US product recall also occurred. Not localized to one region; back-office integration issues.
India pharma market drivers and growth delta — Kunal Dhamesha, Macquarie Capital
PartialMultiple factors: semaglutide launch, field force expansion, base business growth unchanged. Trade generics stable; branded segment growing. Hard to pinpoint exact driver; likely combination of all.
Brazil new launches and scale-up — Nitin Agarwal, DAM Capital
AnsweredBrand extensions in OTC space launched; not major standalone launches yet. Idea is multiple small launches scaling up over 2-3 years to create sizable base.
Semaglutide competitive dynamics — Niharika Agarwal, Nirmal Bang
PartialUnclear durability in off-patent generics; competitive advantage depends on competitor entry speed. Constantly improving costs; price and volume dynamics neutralize each other. Maintaining share is the goal, not price premium.
FY28 EBITDA margin guidance — Madhav Marda, MLP
DodgedNo FY28 guidance yet. Waiting for full-year base to come in; Q1 FY28 will provide FY28 guidance.
Guidance
H2 FY27 India branded growth higher than H1's 10%
MediumAman Mehta: H1 at 10%, H2 expected higher. Total JB growth to recover to double-digit in H2. Integration impact transient.
Brazil double-digit mid-teens growth sustainable
HighSanjay Gupta: Optimistic on momentum from new launches and other businesses; 4 units performing well
US market continues strong with new product launches
High4 products filed YTD, 4-5 more expected before FY end. Market shares above expectations; launches driving growth
EBITDA margin H2 expected little higher than Q2's 33.5%
MediumSudhir Menon: Gradual increase expected; Q3-Q4 to improve modestly. JB EBITDA margins improving sequentially.
Base business margin 0.5% annual improvement trajectory maintained
MediumNo specific FY27 or FY28 margin targets given; directional improvement expected as integration benefits accrue
Risks the call surfaced
JB integration execution
HighIndia branded growth slowed to 7% (vs 20% base business); integration ongoing, margin recovery dependent on execution. Timeline for full synergy realization unclear.
International weakness vs. guidance
MediumInternational segment down 7% YoY, missing prior guidance of high single-digit to low double-digit growth. JB international particularly impacted by integration, but recovery timeline uncertain.
PAT decline amid revenue growth
HighNet profit down 9.6% YoY despite 50.8% revenue growth and 54% EBITDA growth. Suggests integration costs, R&D spend increase (4.2% vs 3.5%), and operating leverage challenges. Bottom-line compression not adequately explained.
Semaglutide market uncertainty
MediumSemaglutide guidance was withdrawn prior call pending recovery trajectory. While call provides recovery narrative (₹800 Cr year-1 market size estimate, 32% share), actual market size and durability are uncertain. New manufacturing partner onboarded, but supply/demand balance not quantified.
Competitive pressure in US generics
MediumSanjay Gupta acknowledges new competitors entering on recent launches; pricing pressure expected in H2. Off-patent generics have flat base fundamentals with price/volume tradeoffs; no durable competitive advantage in mature molecules.
Germany market weakness
LowGermany revenue down 13% constant currency YoY. Management attributes to supply-related issues and government-mandated price decreases. Stabilization expected but timeline uncertain (3-4 quarters suggested).
Management
Score 7/10. Clear on segment-level details (India 20%, Curatio 34%, Brazil 21%, US 13% growth) and integration challenges, but vague on profitability specifics (PAT decline not addressed, FY28 guidance deferred, JB margin convergence unquantified). Transparent on transient impacts but light on execution milestones. Cost synergies tracking ahead of plan (2 years vs 3) is a credible win. Base business growth (20% India, 34% Curatio) supports management's growth narrative. BUT: PAT declined 9.6% despite 50.8% revenue growth and 54% EBITDA growth—suggests operational leverage not yet realized.
1 · H2 FY27
JB integration completion; margin recovery expected as synergies realized
2 · Q3 FY27
Semaglutide supply stabilization post-September restart; market share recovery
3 · Next 6 months
Brazil: 53 ANVISA-pending product approvals; strong pipeline upside
Base business is healthy (India +20%, Curatio +34%), and cost synergies are tracking ahead of plan, but near-term visibility is clouded by JB integration execution risk and international weakness (down 7% vs guidance).